REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Oxygen Containing Hetero Ring > The Hetero Ring Is Six-membered > Polycyclo Ring System Having The Hetero Ring As One Of The Cyclos > Bicyclo Ring System Having The Hetero Ring As One Of The Cyclos (e.g., Chromones, Etc.) Bicyclo Ring System Having The Hetero Ring As One Of The Cyclos (e.g., Chromones, Etc.)Bicyclo Ring System Having The Hetero Ring As One Of The Cyclos (e.g., Chromones, Etc.) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/04/07 - 20070004796 - Processes for the preparation of protected-(+)-catechin and (-)-epicatechin monomers, for coupling the protected monomers with an activated, protected epicatechin monomer, and for the preparation of epicatechin-(4b,8)-epicatechin or -catechin dimers and t Improved processes for the preparation of tetra-O-benzyl protected catechin, for the coupling of the tetra-O-benzyl protected catechin or epicatechin with a C-4 activated, tetra-O-benzyl protected epicatechin for the galloylation of the epicatechin-(4β,8)-catechin or -epicatechin dimer-the dimer digallates, and for the deprotection (i.e., debenzylation) of the protected epicatechin dimers and protected ... 11/23/06 - 20060264500 - Novel flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents wherein R1 through R3 and R5 through R11 are defined herein, and α, β and γ are optional bonds, providing that when α is absent, β is present, and when β is absent, α is present. When α is present, preferred R4 moieties are selected from O, S, NH and ... 11/09/06 - 20060252822 - Mitochrondrial permeability transition pore affinity labels and modulators Methods of utilizing compounds of general formulas I and II as modulators and affinity labels of the MPTP complex are elucidated. Furthermore, methods for modulating the activity of the MPTP complex, methods for determining the presence of a component of the MPTP complex, and methods for identifying an active agent ... 11/09/06 - 20060252821 - Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2h-chroman-6-yl derivatives wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and n have the meanings given in the description, and also a process for the preparation of these compounds and intermediate products of this process. Furthermore, pharmaceutical compositions comprising the compounds of Formula I and related methods of treatment. ... 11/02/06 - 20060247305 - Chromen-4-one inhibitors of anti-apoptotic bcl-2 family members and the uses thereof The invention relates to small molecules which function as inhibitors of anti-apoptotic Bcl-2 family member proteins (e.g., Bcl-2 and Bcl-xL). The invention also relates to the use of these compounds for inducing apoptotic cell death and sensitizing cells to the induction of apoptotic cell death. ... 10/26/06 - 20060241173 - Compound The present invention relates to sulphamate compounds that are an inhibitor of both oestrone sulphatase activity and aromatase activity. ... 10/12/06 - 20060229358 - Pharmaceutical composition containing flavonoids A pharmaceutical composition is provided, where the pharmaceutical composition contains formula (I), (II), or (III) flavonoids which possess selective phosphodiesterase 4 or 4/3 inhibition, as a main ingredient. Especially, this composition is used in the treatment of asthma, chronic obstructive pulmonary disease (COPD), or chronic inflammation, and has bronchodilatory effects. ... 09/14/06 - 20060205807 - Amino-chroman compounds and methods for preparing same The present invention relates to novel amino-chroman compounds, methods of preparing such compounds, and to synthetic intermediates useful in such methods. ... 08/31/06 - 20060194872 - Diamine derivative, production process therefor and antioxidant (wherein, R1, R2, R3 and R4 respectively and independently represent a hydrogen atom or a C1-6 alkyl group, and n represents an integer of 1 or 2) and a production process thereof, as well as an antioxidant that contains the compound as its active ingredient, and a kidney disease treatment ... 08/24/06 - 20060189680 - Apigenin for chemoprevention, and chemotherapy combined with therapeutic reagents Apigenin is a nontoxic compound. The present invention is appropriate for apigenin use in people who have a high risk of getting cancer, and in people who have cancer through chemoprevention and chemotherapy, respectively. We showed that apigenin inhibited cancer cell proliferation, tumor growth and angiogenesis. Apigenin selectively inhibited proliferation ... 08/10/06 - 20060178428 - 7-carboxymethyloxy-3',4',5-trimethoxy flavone monohydrate, the preparation method and uses thereof The present invention relates to 7-carboxymethyloxy-3′, 4′, 5-trimethoxy flavone.monohydrate which is a non hygroscopic product suitable for the preparation of metered dose of 7-carboxymethyloxy-3′, 4′, 5-trimethoxy flavone having protective activity for gastrointestinal tract including the colon, and a preparation method and uses thereof. 7-carboxymethyloxy-3′, 4′, 5-trimethoxy flavone.monohydrate of the present ... 08/03/06 - 20060173071 - Mast cell stabilizers used to inhibit laminitis The invention provides the use of mast cell stabilizers, which composition inhibits excess chemical release such as the mediator of laminitis, histamine, from mast cells for the prevention and/or treatment of laminitis. Mast cell stabilizers can be administered by way of inhalation, oral, subcutaneous, intramuscular or topical. Mast cell stabilizers ... 08/03/06 - 20060173070 - Method of enhancing motor function This invention relates to a method for enhancing physical activities by administering catechins. The combined use of catechin ingestion and exercise makes it possible to promote the oxidation of fat and hence, to inhibit obesity, liver enlargement and diabetes. ... 08/03/06 - 20060173069 - Therapeutic agent for hyperpotassemia and bone disease (R represents a hydroxyl-protecting group releasable under acidic conditions.) ... 07/20/06 - 20060160889 - Chroman derivatives as estrogenic compounds wherein R1 is (1C-4C)alkyl, (2C-4C)alkenyl or (2C-4C)alkynyl, and independently R1 has a cis-orientation in relation to the exocyclic phenyl group at the 2-position of the skeleton; R4 is H, Hal, CF3, OH or (1C-2C)alkyloxy; R2, R3, and R5are independently H, Hal, CF3, (1C-4C)alkyl, (2C-4C)alkenyl or (2C-4C)alkynyl and prodrugs thereof for ... 07/06/06 - 20060148888 - Chroman derivatives and uses thereof wherein m, p, q, Ar, R1, R2, R3 and R4 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formula I. ... 06/29/06 - 20060142379 - Use of ap-1 activators to treat glaucoma and ocular hypertension Compositions comprising AP-1 activators and methods of use for treating glaucoma and ocular hypertension are disclosed. ... 06/08/06 - 20060122262 - Use of equol for treating androgen mediated diseases Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These ... 05/25/06 - 20060111435 - Compositions for treating or preventing obesity and insulin resistance disorders Provided herein are methods and compositions for modulating the activity or level of a sirtuin, thereby treating or preventing obesity or an insulin resistance disorder, such as diabetes in a subject. Exemplary methods comprise contacting a cell with a sirtuin activating compound or an inhibitory compound to thereby increase or ... 05/25/06 - 20060111434 - Method for preparing derivatives of fungicidal iodochromones This invention relates to new methods for preparing chemical compounds, in particular fungicidal compounds, especially iodinated derivatives of chromones, preferably compounds of formula (I), and intermediate compounds useful for these methods. ... 05/18/06 - 20060106092 - Procyanidin b dimers for aromatase inhibition Anti-aromatase procyanidin B suppresses estrogen production, thus preventing or treating estrogen-related diseases such as breast tumors, hormone-dependent tumors and hormone-related disorders. ... 05/18/06 - 20060106091 - Antigiardial agents and use thereof The present invention provides a method of preventing or treating one or more of the following medical conditions, or treating symptoms of one or more of the following medical conditions: amebic infections, giardiasis, estrogen deficient states, osteoporosis, cardiovascular heart disease, high cholesterol levels, hyperlipidemia, cancer by administering to a subject ... 04/27/06 - 20060089404 - Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders A class of chromane and chromene compounds having the structure shown below and pharmaceutically acceptable salts thereof are useful as therapeutic compounds, particularly in the treatment and control of hyperlipidemia, hypercholesterolemia, dyslipidemia, and other lipid disorders, and in delaying the onset of or reducing the risk of conditions and sequelae ... 04/06/06 - 20060074127 - Substituted chroman derivatives, medicaments and use in therapy Novel substituted chroman derivatives and intermediate compounds, compositions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotherapeutic selective agents are described. ... 04/06/06 - 20060074126 - Chroman derivatives, medicaments and use in therapy Novel chroman derivatives and intermediate compounds, compositions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotherapeutic selective agents are described. ... 03/30/06 - 20060069151 - Novel use of lycopene Lycopene can be used in the primary prevention and incidence risk reduction of non-cancerous symptoms and/or pathologies (i.e., the prophylactic supplementation of the healthy subjects), in the treatment or the coadjuvant treatment of non-can-cerous symptoms and/or pathologies (i.e. the supplementation as therapy or accompanying a running therapy) and in the ... 03/09/06 - 20060052441 - Procyanidin and nitric oxide modulator compositions This invention relates to an article of manufacture comprising a polymeric compound of formula An and an additional NO-modulating agent and method of use thereof. Also disclosed and claimed is a method of making an article of manufacture comprising of the polymeric compound of formula An. ... 03/09/06 - 20060052440 - Medicinal composition for treating sudden deafness The pharmaceutical composition of the present invention for treating sudden deafness containing, as an active ingredient, isoflavone aglycone derived from soybean germ can be used to prevent sudden deafness in humans by manifesting an action that is effective in treating disease in humans. The pharmaceutical composition for treating sudden deafness ... 02/23/06 - 20060041010 - (-)-epigallocatechin gallate derivatives for inhibiting proteasome (−)-EGCG, the most abundant catechin, was found to be chemopreventive and anticancer agent. However, (−)-EGCG has at least one limitation: it gives poor bioavailability. This invention provides compounds of generally formula 10, wherein R1 is selected from the group of —H and C1 to C6 acyl group; R2, R3, and ... 01/26/06 - 20060020023 - Racemization method This invention relates to a method for racemizing enantiomers of a substituted 2-trifluoromethyl-2H-chromene-3-carboxylic acid or ester, a substituted 2-trifluoromethyl-1,2-dihydro-quinoline-3-carboxylic acid or ester, a substituted 2-trifluoromethyl-2H-thiochromene-3-carboxylic acid or ester, or a pharmaceutically acceptable salt of the acids or esters, using secondary amines, and optionally hydroxides, alkoxides, or sulfites at reaction mixture ... 01/26/06 - 20060020022 - Enantioselective separation method This invention relates to a method for separating enantiomers of a substituted 2-trifluoromethyl-2H-chromene-3-carboxylic acid or ester, a substituted 2-trifluoromethyl-1,2-dihydro-quinoline-3-carboxylic acid or ester, a substituted 2-trifluoromethyl-2H-thiochromene-3-carboxylic acid or ester, a substituted 3-trifluoromethyl-3,4-dihydro-naphthalene-2-carboxylic acid or ester, or a pharmaceutically acceptable salt of the acids or esters, using enantioselective fractional crystallization, enantioselective high ... 01/26/06 - 20060020021 - Use of compounds derived from 2,3-dehydronaringenin for the treatment of inflammatory processes and pharmaceutical composition containing said derivatives The present invention refers to the use of 2,3-dehydronarinegenin (apigenin) derivatives of Formula (I) for the treatment or prophylaxis of inflammatory processes and chronic diseases derived from inflammatory processes, as well as to a pharmaceutical composition containing them, together with excipients. ... 12/29/05 - 20050288361 - Dendrite elongation inhibitor for melanocyte and skin preparation for external use containing the same wherein R1, R2, and R3 each independently represent a C1-4 alkyl group or hydrogen atom, and a skin preparation for external use comprising the dendrite elongation inhibitor for melanocytes as an active ingredient. ... 12/29/05 - 20050288360 - Nutraceutical compositions comprising epigallocatechin gallate and raspberry ketone Compositions comprising epigallocatechin gallate and 4-(4-hydroxyphenyl)-2-butanone may be used for the treatment or prevention of obesity or conditions associated with obesity such as non-insulin-dependent diabetes mellitus (NIDDM, type II) and syndrome X. The compositions may find use in the nutritional field as a supplement to food and beverages, as well ... 12/08/05 - 20050272810 - Compositions comprising nebivolol Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention features a pharmaceutical composition comprising nebivolol and at least one other active agent, wherein the at least one other active agent is a cardiovascular ... 12/08/05 - 20050272809 - Remedies wherein R1 and R2 are taken together with the carbon atom to which they are bound, respectively, to form a hydroxydimethyl hexane ring, or where R1 is a hydroxyl group, R2 is an isohexenyl group, a derivative thereof, or a salt thereof. Also, the present invention relates to a therapeutic ... 12/01/05 - 20050267202 - Chromanol derivatives, a process for their production and their use as anti-inflammatory agents a process for their production, and their use as anti-inflammatory agents. ... 11/10/05 - 20050250845 - Pseudopolymorphic forms of a hiv protease inhibitor New pseudopolymorphic forms of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate and processes for producing them are disclosed. ... 11/03/05 - 20050245602 - Selective estrogen receptor modulators The present invention provides, inter alia, triphenylethylene derivatives, such as, 3-{4-[6-(3-Methoxy-phenyl)-8,9-dihydro-7H-benzocyclohepten-5-yl]-phenyl}-acrylic acid, as selective estrogen receptor modulators. Also provided are methods for treating estrogen stimulated diseases in mammals including, but not limited to, for example, breast, uterine, ovarian, prostate and colon cancer; osteoporosis; endometriosis; uterine fibroid; Alzheimer's disease; macular degeneration; ... 11/03/05 - 20050245601 - Treatment of diseases involving erbb2 kinase overexpression This invention relates to compositions containing polyphenols such as flavanols and their related oligomers, and methods for treating conditions associated with ErbB2 kinase overexpression, for example, treatment of cancers involving ErbB2 kinase overexpression. ... 11/03/05 - 20050245600 - Novel antimalarial agent A novel antimalarial agent. It is a medical composition comprising a pharmaceutically acceptable carrier and a compound represented by the general formula (I), wherein R1 to R12 is independently, hydrogen, halogen, hydroxy, alkyl, alkoxy, amino or acylamino. ... 10/13/05 - 20050228040 - Bicyclic aromatic sulfinyl derivatives wherein the constituent members are defined herein, including pharmaceutical compositions thereof and methods of treating diseases therewith. ... 10/13/05 - 20050228039 - Luminacin analogs and uses thereof and additionally provides methods for the synthesis thereof and methods for the use thereof in the treatment of cancer, wherein R1-R14 and n are as defined herein. ... 10/06/05 - 20050222248 - Isoflavone metabolites There are disclosed compounds of formulae (I) or (II) in which A is selected from the group consisting of (1), (2), (3) and (4);OH, and one of R1 and R2 is selected from H, OH and OCH3, and the other of R1 and R2 is selected from OH and OCH3; ... 10/06/05 - 20050222247 - Chroman derivatives This invention relates to chroman derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The chroman derivatives of the present invention have an excellent activity as BETA 3 antagonists and are useful for the prophylaxis and treatment of diseases associated with BETA 3 activity, in particular ... 09/29/05 - 20050215623 - Palatability of aquaculture feed wherein R1, R2, R3, and n are as defined herein, are disclosed. ... 09/22/05 - 20050209314 - Novel benzopyran analogs and their use for the treatment of glaucoma Novel benzopyran analogs are disclosed. Also disclosed are methods for the lowering and controlling of normal or elevated intraocular pressure as well as a method for the treatment of glaucoma using compositions containing one or more of the compounds of the present invention. ... 09/22/05 - 20050209313 - Flavonoid concentrates A method of producing a flavonoid aglycone concentrate from plant material containing a suitable flavonoid glycoside and/or conjugate thereof comprising the steps of: (i) enzymatically converting the flavonoid glycoside or conjugate thereof into the flavonoid aglycone; and (ii) adjusting the pH to render the flavonoid aglycone relatively insoluble and forming ... 09/15/05 - 20050203173 - Pi-3 kinase inhibitor prodrugs The invention provides novel prodrugs of inhibitors of PI-3 kinase. The novel compounds are LY294002 and analogs thereof comprising a reversibly quaternized amine. ... 09/01/05 - 20050192342 - Chroman-derived anti-androgens for treatment of androgen-mediated disorders Methods for the prevention and/or alleviation of androgen-mediated disorders treatable by administering a chroman-derived anti-androgen compound are provided by the present invention. The invention further provides pharmaceutical and nutraceutical compositions containing chroman-derived anti-androgen compounds useful in the prevention and/or alleviation of androgen-mediated disorders, particularly prostate cancer. ... 08/11/05 - 20050176810 - Chondropsin-class antitumor v-atpase inhibitor compounds, compositions and methods of use thereof A substantially purified compound of the formula: a composition comprising a therapeutically effective amount of at least one compound of the formula, alone or in combination with at least one additional therapeutic agent, and methods of preventing or treating cancer and a condition treatable by the inhibition of vacuolar-type (H+)-ATPase ... 07/28/05 - 20050165090 - Polyphenols as an intravesical agent for the prevention of transitional cell tumor implantation A method and pharmaceutical composition for treating the bladder cancer in a mammal includes intravesically administrating to a mammal in need of bladder cancer treatment a therapeutically effective amount of a composition comprising at least one polyphenol and in particular EGCG, within the mammal's bladder. ... 07/28/05 - 20050165089 - Compounds, compositions and methods Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed. ... 07/07/05 - 20050148659 - Amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2h-chromen-6-yl compounds, a process and intermediates for their production, and pharmaceutical compositions containing them in which R1, R2, R3, R4, R5 and R6 have the meanings given in the description; a process for the preparation of these compounds; intermediate products used to prepare such compounds, and pharmaceutical compositions containing such compounds. ... 07/07/05 - 20050148658 - Method for preventing and treating severe acute respiratory syndrome A composition and method for preventing and treating SARS utilizes theaflavin and its derivatives in combination with a carrier. ... 06/30/05 - 20050143449 - Non-steroidal farnesoid x receptor modulators and methods for the use thereof The efficient regulation of cholesterol synthesis, metabolism, acquisition, and transport is an essential component of lipid homeostasis. The farnesoid X receptor (FXR) is a transcriptional sensor for bile acids, the primary product of cholesterol metabolism. Accordingly, the development of potent, selective, small molecule agonists, partial agonists, and antagonists of FXR ... 06/16/05 - 20050131060 - Compositions useful for the treatment of pathologies responding to the activation of ppar-gamma receptor This invention features the use of the spirolaxine of formula (I) for the treatment of those pathologies responding to the activation of the PPARγ receptor, such as the Type 2 insulin-resistant diabetes. This invention also features a pharmaceutical composition in which the spirolaxine of formula (I) acts as active principle ... 06/16/05 - 20050131059 - Anti-cancer combinations The present invention relates to synergistic combinations of the compounds of formula I such as compounds of the xanthenone acetic acid class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and NSAIDs, in particular diclofenac, which have anti-tumour activity. More particularly, the invention is concerned with the use of such combinations in the ... 06/02/05 - 20050119335 - Environmentally safe anti-fungal composition and methods of using same Disclosed herein or novel, environmentally friendly compositions and methods for treating or preventing fungal growth, such as molds and mildew, on surfaces and in objects. Specifically exemplified herein are compositions containing nepetalactone, and methods of using same. ... ### FreshPatents.com Support |